Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital. Preliminary PET imaging data from the study show encouraging signals in acute MS lesions, suggesting that the novel imaging technique may be able to distinguish between demyelinated nerve fibers that could still recover and those that have suffered permanent damage. This capability is critical for accurately measuring myelin loss and repair, which are central to the progression of MS.
The findings are directly relevant to Lucid-MS, the company's investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation. A more precise imaging tool combined with a drug candidate that addresses the underlying cause of MS could be a powerful combination. Reaching the enrollment midpoint with promising early data suggests that the science is holding up under real clinical conditions, lending credibility to the potential of both the imaging technique and the therapeutic approach.
For a detailed analysis, readers can refer to the full article at https://nnw.fm/fsDHa.
Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation—the underlying mechanism of MS. The potential of Lucid-MS is underscored by the encouraging imaging data, which could facilitate more effective clinical trials and regulatory approval.
The company has also spun out its OTC product, unbuzzd, to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty rate drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses.
Investors and stakeholders should note that forward-looking statements in this article involve risks and uncertainties, as detailed in the company's filings with the SEC. For more information on Quantum BioPharma and its latest updates, visit the company's newsroom at https://ibn.fm/QNTM.
This development is significant because it provides early clinical validation for a novel imaging biomarker that could transform how MS is monitored and treated. If the imaging technique proves reliable, it could accelerate the development of remyelinating therapies like Lucid-MS, offering hope to millions affected by MS worldwide.
